org placeholder image

John Mc Mannis

Consultant, Cellular Therapies at Mesoblast Limited

  • LinkedIn

Email Email: j****@mesoblast.com

phone noPhone Number: (***)-***-****

map
MESOBLAST LIMITED

MESOBLAST LIMITED

  • description Description
    Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical ne...

    Read More

  • Employees count Employees 51-200
  • Revenue Revenue 25 Million to 50 Million
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Mesoblast Limited Org Chart and Mapping

Employees

Christopher James

Vice President, Clinical Operations

Susan Sukovich

Senior Director Regulatory Affairs

John McMannis

Consultant, Cellular Therapies

Michael Dimuro

Senior Director Project Management

Jodie Wehling

Vice President of Managed Markets and Sales

David Núñez

Director Clinical Development

Frequently Asked Questions Regarding John McMannis

Answer: John Mc Mannis works for Mesoblast Limited as Consultant, Cellular Therapies

Answer: John Mc Mannis’s role in Mesoblast Limited is Consultant, Cellular Therapies

Answer: John Mc Mannis's email address is j***@gmail.com

Answer: John Mc Mannis's business email address is j****@mesoblast.com

Answer: John Mc Mannis’s direct phone number is (***)-***-****

Answer: John Mc Mannis works in the industry of: Biotechnology

Answer: John Mc Mannis works Mesoblast Limited located at 505 5th Ave, Melbourne, New York, 10017, United States

Answer: Mesoblast Limited's Consultant, Cellular Therapies is John Mc Mannis

Answer: John McMannis contact details:

  • Phone number  :  (***)-***-****
  • Email  :  j****@mesoblast.com

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access